Last reviewed · How we verify
Lubiprostone 24
Lubiprostone is a ClC-2 chloride channel activator that increases intestinal fluid secretion and promotes bowel motility to relieve constipation.
Lubiprostone is a ClC-2 chloride channel activator that increases intestinal fluid secretion and promotes bowel motility to relieve constipation. Used for Chronic idiopathic constipation, Irritable bowel syndrome with constipation (IBS-C), Opioid-induced constipation.
At a glance
| Generic name | Lubiprostone 24 |
|---|---|
| Also known as | Amitiza |
| Sponsor | Sucampo Pharma Americas, LLC |
| Drug class | ClC-2 chloride channel activator |
| Target | ClC-2 chloride channel |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Lubiprostone activates ClC-2 chloride channels on the apical membrane of gastrointestinal epithelial cells, increasing chloride and fluid secretion into the intestinal lumen. This increased fluid content enhances stool consistency and promotes normal bowel function, providing relief from chronic idiopathic constipation and other constipation-related conditions.
Approved indications
- Chronic idiopathic constipation
- Irritable bowel syndrome with constipation (IBS-C)
- Opioid-induced constipation
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Vomiting
Key clinical trials
- Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer (PHASE2)
- Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation (PHASE3)
- The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation
- Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease (PHASE3)
- Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy (PHASE2)
- Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation (PHASE4)
- Amitiza in Constipation Associated With PD (Parkinson's Disease) (PHASE4)
- Lubiprostone for Functional Constipation in the Under 18 Years Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lubiprostone 24 CI brief — competitive landscape report
- Lubiprostone 24 updates RSS · CI watch RSS
- Sucampo Pharma Americas, LLC portfolio CI